Perhexiline ( DrugBank: Perhexiline )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
58	Hypertrophic cardiomyopathy	5
272	Fibrodysplasia ossificans progressiva	1

58. Hypertrophic cardiomyopathy

---

Clinical trials : 119 /  Drugs : 163 - (DrugBank : 45) / Drug target genes : 48 - Drug target pathways : 161

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04426578 (ClinicalTrials.gov)	December 1, 2020	14/5/2020	Role of Perhexiline in Hypertrophic Cardiomyopathy	Randomised Controlled Trial of pErhexiline on regreSsion Of Left Ventricular hypErtrophy (LVH) in Patients With Symptomatic Hypertrophic CardioMyopathy (RESOLVE-HCM)	Hypertrophic Cardiomyopathy	Drug: Perhexiline;Other: Placebo	Flinders University	NULL	Recruiting	18 Years	N/A	All	60	Phase 2	Australia
2	NCT02862600 (ClinicalTrials.gov)	August 1, 2016	8/8/2016	Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure	A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function	Cardiomyopathy, Hypertrophic;Cardiomyopathy, Hypertrophic, Familial	Drug: Perhexiline;Device: Use of bioanalytical assay to monitor plasma levels of perhexiline	Heart Metabolics Limited	NULL	Terminated	18 Years	N/A	All	35	Phase 2	United States
3	NCT02431221 (ClinicalTrials.gov)	July 22, 2015	27/4/2015	Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure	A Study on the Efficacy, Safety, and Tolerability of Perhexiline Maleate in Subjects With Hypertrophic Cardiomyopathy and Moderate-To-Severe Heart Failure	Hypertrophic Cardiomyopathy	Drug: Perhexiline;Drug: Placebo	Heart Metabolics Limited	NULL	Withdrawn	18 Years	N/A	All	0	Phase 3	NULL
4	NCT00500552 (ClinicalTrials.gov)	December 2006	10/7/2007	Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy	Metabolic Alteration With Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy (METAL-HCM Study)	Hypertrophic Cardiomyopathy	Drug: Perhexiline/Placebo	University Hospital Birmingham	British Heart Foundation;University College London Hospitals;University of Oxford	Completed	18 Years	80 Years	Both	44	Phase 2	United Kingdom
5	EUCTR2005-000755-15-GB (EUCTR)	25/10/2005	27/05/2005	Perhexiline therapy in patients with Hypertrophic Cardiomyopathy	Perhexiline therapy in patients with Hypertrophic Cardiomyopathy	Hypertrophic Cardiomyopathy	Product Name: Pexsig INN or Proposed INN: Perxexiline	University Hospital of Birmingham Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50		United Kingdom

Back to top

272. Fibrodysplasia ossificans progressiva

---

Clinical trials : 40 /  Drugs : 36 - (DrugBank : 6) / Drug target genes : 27 - Drug target pathways : 95

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000019348	2010/07/01	14/10/2015	Approved calcium channel blocker in the treatment of fibrodysplasia ossificans progressiva (FOP)		fibrodysplasia ossificans progressiva	oral administration of perhexiline maleate for one year	Nagoya University Graduate School of Medicine	NULL	Complete: follow-up complete	15years-old	65years-old	Male and Female	5	Phase 1,2	Japan

Back to top